 GAITHERSBURG, Md., Nov. 12, 2021 GLOBE NEWSWIRE -- MaxCyte, Inc., NASDAQ: MXCT; LSE: MXCT, MXCN, a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialization, today announced Company management will participate in the following investor conferences: 